Full-Time

Senior Scientist / Principal Scientist

Medicinal Chemistry

General Proximity

General Proximity

11-50 employees

Seed-stage platform for induced proximity drugs

No salary listed

San Francisco, CA, USA

In Person

On-site role; located at MBC BioLabs, 135 Mississippi Street, San Francisco, CA.

PhD

Category
Biology & Biotech (1)
Required Skills
Medicinal Chemistry
Biochemical Assays

Get referred to General Proximity

See people who can refer or advise you

Requirements
  • PhD in Chemistry, Medicinal Chemistry, or a related field
  • A minimum of 5 years of industry experience in small-molecule drug discovery
  • Strong foundation in medicinal chemistry and its application to disease-focused drug discovery
  • Experience designing, synthesizing, and optimizing induced proximity medicines, including PROTACs or related approaches
  • Experience across hit finding, hit-to-lead, and lead optimization, including experience building follow-up strategy for HTS, DNA-encoded or phenotypic screening follow-up
  • Demonstrated success optimizing compounds for oral exposure and interpreting pharmacokinetic data across multiple species
  • Deep understanding of physicochemical properties and in vitro DMPK parameters, including solubility, permeability, metabolic stability, and plasma protein binding, and how to apply them to lead optimization
  • Experience managing external chemistry CROs and driving synthetic programs efficiently
  • Excellent written and verbal communication skills
Responsibilities
  • Design and advance medicinal chemistry strategies for next-generation induced proximity medicines, including bifunctional and molecular glue-related modalities
  • Lead compound design and SAR campaigns from hit finding and HTS follow-ups through hit-to-lead and lead optimization
  • Manage external chemistry CROs, including compound design prioritization, synthetic execution, timelines, and data review
  • Direct external DMPK studies and interpret in vitro and in vivo data to guide compound progression
  • Partner closely with Biology and Platform teams to design screening strategies and support compound evaluation in biochemical, biophysical, and cellular assays
  • Contribute to mechanistic studies that strengthen understanding of lead molecules and inform program direction
  • Support intellectual property strategy through invention generation and contributions to patent filings
  • Help evaluate and expand opportunities into new disease areas and therapeutic applications
Desired Qualifications
  • Experience contributing to programs that advanced from discovery into clinical development
  • Background in computational chemistry, molecular modeling, or molecular dynamics
  • Familiarity with chemical biology or structural biology techniques, including assay development, compound profiling, pulldown experiments, protein purification, or crystallography
  • Experience with HTS or phenotypic screening
  • Experience in proteomics, including PTM analysis or chemoproteomic target deconvolution

Preparing a concise company summary based on provided description.

Company Size

11-50

Company Stage

Seed

Total Funding

$16.1M

Headquarters

San Francisco, California

Founded

2019

Get referred to General Proximity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FreeMind and Daewoong invested on May 4, 2026, adding strategic Asian commercial reach.
  • ARPA-H and NCI grants de-risk non-dilutive financing for 2026 preclinical work.
  • General Proximity raised $28 million total and expanded July 2026 hiring momentum.

What critics are saying

  • General Proximity still has no public IND or named clinical asset as of July 2026.
  • Platform biology remains unproven clinically; Daiichi Sankyo and Daewoong can walk away.
  • Larger rivals like Revolution Medicines, Nurix, and C4 Therapeutics crowd induced-proximity oncology.

What makes General Proximity unique

  • OmniTAC scans effectors broadly, not one degradation pathway, widening target access.
  • Daiichi Sankyo signed a multi-target oncology collaboration on November 12, 2025.
  • General Proximity says its lead program is internally discovered and best-in-class.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

15%
Noah Business Intelligence
Jul 6th, 2026
General Proximity Bio raises $28M across seed and pre-Series A for induced-proximity drug platform

San Francisco biotech General Proximity Bio has secured notable early-stage investment for its induced-proximity medicine platform. The company emerged from stealth in January 2025 with $16 million in seed funding led by Felicis Ventures, alongside Y Combinator, age1, and other investors. It subsequently closed an oversubscribed $12 million pre-Series A round, attracting strategic investment from Daewoong Pharmaceutical and FreeMind Investments. General Proximity also received non-dilutive support through grants from ARPA-H and the National Cancer Institute. The platform targets proteins traditionally considered difficult to drug, focusing on cancer, cardiometabolic disease, neurodegeneration, and longevity. The company remains preclinical with no public IND filing or lead asset. Scientific challenges in proximity-based drug design include selectivity, pharmacokinetics, oral delivery, and off-target effects. General Proximity is pursuing a platform approach rather than developing a single near-term product.

Yonhap Infomax
Apr 30th, 2026
Daewoong Pharmaceutical invests in US biotech General Proximity for induced proximity drug development

Daewoong Pharmaceutical has invested in US biotech firm General Proximity alongside venture capital fund Freemind Investment to collaborate on new drug development. The investment amount was not disclosed. The partnership aims to secure "induced proximity" technology, a next-generation drug development method that regulates protein function by bringing disease-related proteins and regulatory proteins together. This approach differs from conventional methods that required drugs to fit precisely into specific binding sites, potentially expanding treatment options for previously inaccessible proteins. Founded in 2019, General Proximity possesses a platform for discovering induced proximity therapeutics based on Effectome scanning technology. The company is developing new drug pipelines in oncology, cardiovascular and metabolic diseases, and neurodegenerative diseases.

Business News Today
Nov 12th, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

VCNewsDaily
Jan 3rd, 2025
General Proximity Raises $16M Funding

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.

PR Newswire
Jan 3rd, 2025
General Proximity Raises $16M for Undruggable Targets

General Proximity has emerged from stealth with $16M to develop treatments for undruggable proteins linked to cancer, cardiometabolic disease, neurodegeneration, and longevity using its OmniTAC platform. The $8M seed round was led by Aydin Senkut at Felicis. Other investors include Y Combinator and Jim Dahl. The company aims to revolutionize drug discovery with a potential market exceeding $250 billion annually.